# Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

> **NCT02057172** · PHASE2 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 254 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** HM11260C
- **DRUG:** liraglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02057172
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-10
- **Final completion:** 2014-12
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2016-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02057172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02057172, "Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02057172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*